EPI-743 Improves Motor Function and CNS Biomarkers in PD: Results From a Phase 2A Pilot Trial

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Glutamic Acid 100%
• Glutamine 100%
• Vatiquinone 50%
• Oxidoreductase 50%
• Glutathione 50%
• Investigational Drug 50%
• Adverse Event 50%
• Open-Label Trial 50%
• Disease 50%

Biochemistry, Genetics and Molecular Biology

• Motor Performance 100%
• Oxidative Stress 100%
• Glutamine 66%
• Magnetism 66%
• Primary Cell 33%
• Energy Transfer 33%
• Alpha-Tocotrienol 33%
• Metabolite 33%
• Mann-Whitney U Test 33%
• Metabolic Pathway 33%
• Drug Targeting 33%
• Glutathione 33%
• Oxidoreductase 33%